Last reviewed · How we verify
Human spinal cord stem cells. — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Human spinal cord stem cells. (Human spinal cord stem cells.) — Neuralstem Inc..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Human spinal cord stem cells. TARGET | Human spinal cord stem cells. | Neuralstem Inc. | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Human spinal cord stem cells. CI watch — RSS
- Human spinal cord stem cells. CI watch — Atom
- Human spinal cord stem cells. CI watch — JSON
- Human spinal cord stem cells. alone — RSS
Cite this brief
Drug Landscape (2026). Human spinal cord stem cells. — Competitive Intelligence Brief. https://druglandscape.com/ci/human-spinal-cord-stem-cells. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing